UPSTREAM BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
UPSTREAM BIO, INC. (UPB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.91 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 597.73K shares, a 24.38% increase year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.32M shares, a 16.37% decline year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 48.00K shares, a 81.76% decline year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 121.00K shares.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.22M shares, a 35.98% decline from fiscal 2024.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.47M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 597.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.91M shares 10-Q · filed 2026-08-11 | 1.96M shares derived: sum of 3 quarters · filed 2026-08-11 | 2.08M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 1.32M shares 10-Q · filed 2026-05-13 | 1.36M shares derived: sum of 2 quarters · filed 2026-05-13 | 1.48M shares derived: sum of 3 quarters · filed 2026-05-13 | 1.97M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 48.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 169.00K shares derived: sum of 2 quarters · filed 2026-03-26 | 649.58K shares derived: sum of 3 quarters · filed 2026-03-26 | 2.22M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 121.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 601.58K shares derived: sum of 2 quarters · filed 2025-11-05 | 2.17M shares 10-Q · filed 2025-11-05 | 2.44M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 480.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 2.05M shares 10-Q · filed 2025-08-06 | 2.32M shares derived: sum of 3 quarters · filed 2025-08-06 | |
| 2025-03-31 | 1.57M shares 10-Q · filed 2025-05-06 | 1.84M shares derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2024-12-31 | 263.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | 3.47M shares 10-K · filed 2025-03-12 | ||
| 2024-09-30 | 3.21M shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |